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Summary 
Background. Obesity, type 2 diabetes (T2D), dyslipidemia, arterial hypertension as well as hepatic 
steatosis (HS) are common conditions that can affect clinical outcomes of patients with chronic 
hepatitis C (CHC) who achieved sustained virological response (SVR). The aim of this study was to 
assess the impact of metabolic cofactors on the occurrence of clinical events during follow-up (FU) 
in a group of CHC long term responders (LTRs) to interferon (IFN) -based therapy. 
Methods. A total of 5172 medical records of CHC patients enrolled from 1990 to 2011 were 
examined. 1034/5172 (20%) patients were treated with IFN-based therapy and 382/1034 (37%) of 
them achieved SVR. A total of 188 (49%) LTRs performed liver biopsy before antiviral treatment. 
Data on liver and cardiometabolic events such as cirrhosis and its complications, hepatocellular 
carcinoma, coronary artery disease, arterial hypertension, impaired fasting glucose (IFG)/type 2 
diabetes (T2D) and dyslipidemia, were collected over time.  
Results. The mean age of the whole cohort was 46 ± 12 years and 114/188 (61%) patients were 
males. HS was found in 82/188 (43.6%) patients and most of them were infected by HCV genotype 
3a. The prevalence of obesity, IFG/T2D, dyslipidemia and arterial hypertension was 4.3%, 6.9%, 
37.2% and 5.9%, and was similarly distributed among patients with and without HS. Cirrhosis was 
histologically diagnosed in 18/188 (9.6%) patients. After a median follow-up of 11 years (range 3-
21), the cumulative incidence of cardiovascular events, IFG/T2D and dyslipidemia was higher in 
CHC-LTRs who had HS at baseline compared to those without HS (1.2%, 2.3% and 3.0% vs 0.4%; 
0.8% and 2.5%, respectively). At multivariable Cox regression analysis, HS was significantly 
associated to the development of cardiovascular events and IFG/T2D (HR=5.2, 95%CI=1.3-20.7, 
p=0.019 and HR=2.6, 95%CI=1.1-6.2, p=0.027, respectively). 
Conclusions. In CHC-LTRs, HS at baseline may predispose to the development of cardiovascular 
events and T2D during follow-up emphasizing the importance of an accurate counseling in order to 
prevent extra-hepatic complications. 
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Introduction 
For nearly 30 years, interferon (IFN) alone or in combination with ribavirin (RBV), has been the 
gold standard for the treatment of hepatitis C virus (HCV) infection. The rate of treatment success is 
closely linked to viral and host factors such as HCV-genotype, patient age, sex, genetic factors, 
stage of liver fibrosis and the presence of other comorbidities.1-2 Sustained virological response 
(SVR), defined as undetectable HCV-RNA 24 weeks after the end of therapy, was achievable in 
75% of patients infected with genotypes 2 and 3 and only in 40–50% of patients infected with 
genotype 1. 3-5 It is well known that viral eradication improves liver histology, quality of life and 
reduces the risk to develop cirrhosis and hepatocellular carcinoma (HCC).6-7  Metabolic cofactors 
such as obesity, insulin resistance (IR), type 2 diabetes (T2D) and dyslipidemia may impact on the 
morbidity and mortality of chronic hepatitis C (CHC) accelerating the progression of liver fibrosis, 
increasing the risk of developing HCC and reducing the response to antiviral therapy.8-9 From a 
metabolic point of view, HCV infection resembles non-alcoholic steatohepatitis (NASH) for the 
impairment of glucose metabolism even if the signaling pathways involved are different. The 
prevalence of hepatic steatosis (HS) in the setting of CHC is around 40% 10 while the risk to 
develop T2D is higher compared to the other chronic liver diseases suggesting a potential 
diabetogenic effect of the virus.10 Specifically, HCV core protein impairs insulin pathway 
increasing the phosphorylation of insulin receptor substrate-1 (IRS-1) through the up-regulation of 
the suppressor of cytokine signaling (SOCS) that in turn impairs insulin signaling. In HCV 
genotype 3 patients, the up-regulation of SOCS leads to a down-regulation of the peroxisome 
proliferator-activated receptor-g (PPARg) promoting HS thus IR.11-12 Conversely, in patients with 
non-3 HCV genotypes, HS is associated with body mass index (BMI) and IR and may persist even 
if the viral infection is resolved.10,13   
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Similarly, HCV can affect lipid metabolism through its interaction with very low density 
lipoproteins (VLDL) and low density lipoproteins (LDL). The association of HCV with host 
lipoproteins facilitates its entry into the hepatocytes favoring the development of chronic liver 
disease.14 The association between HCV infection and metabolic alterations may predispose to the 
development of clinical events over time notwithstanding viral eradication, accelerating liver 
fibrosis. In CHC patients who achieved SVR after IFN+RBV therapy, the assessment of metabolic 
derangement is crucial for their management to prevent the occurrence of hepatic and cardio-
metabolic events over time. Furthermore, this strategy remains important also in the era of the new 
drugs named direct antiviral agents (DAAs) characterized by a high HCV eradication rate.15 In this 
context, the aim of this study was to define the main baseline metabolic predictors of clinical 
outcomes in a monocentric cohort of CHC-LTRs who underwent liver biopsy at the time of HCV 
antiviral therapy. 
   
Materials and Methods 
Patients 
From 1990 to 2011, a total of 5172 patients were approached at the Division of Gastroenterology 
and Hepatology, Città della Salute e della Scienza University Hospital, Turin. All the available 
medical records were retrospectively examined. Patients included in the study were infected with 
HCV, underwent IFN-based therapy (IFN mono-therapy or pegylated IFN plus RBV) and achieved 
a SVR (Figure 1). Patients with HCV/HBV coinfection (N=12), with a follow-up period less than 3 
years (N=35) and without liver biopsy prior to treatment (N=147) were excluded from the analysis 
(Figure 1).  
Antiviral therapy duration was 48 weeks or less according to specific guidelines.5 The beginning of 
follow-up for each patient started at the initiation of antiviral therapy while the end coincided with 
the last medical examination available (at least three years after the end of treatment). Long-term 
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response was defined as the maintenance of SVR throughout follow-up which had an average of 10 
years (range 3-21 years). Liver enzymes (AST, ALT, GGT) and metabolic parameters (total-
cholesterol, triglycerides, glucose), BMI and instrumental examination (abdominal ultrasound [US]) 
were collected from medical records prior to treatment initiation and at the last available follow-up 
visit. Liver biopsies were analyzed at baseline by an expert pathologist. Hepatic fibrosis and 
inflammation were scored according to Ishak classification.16 Steatosis was defined as absent or 
significant if the percentage of fat into the hepatocytes was less than 5% or ≥ 5%, respectively. 
All patients gave their consent for including their personal data in the database. The study was 
approved by the ethics committee of the University Hospital Città della Salute e della Scienza of 
Turin and was in accordance with the Helsinki Declaration.      
 
Metabolic cofactors definition 
Metabolic cofactors considered in this study were: overweight/obesity (BMI ≥ 24.9 kg/m2/BMI ≥ 
29.9 kg/m2), impaired fasting glucose (IFG)/T2D (fasting glucose levels ≥ 110 mg/dl), dyslipidemia 
(total cholesterol ≥ 200 mg/dl, triglycerides ≥ 150 mg/dl), arterial hypertension (≥ 130/85 mm/Hg) 
and HS at biopsy (≥ 5%).  
 
Follow up and clinical outcomes 
All the patients were followed-up for at least 3 years (median FU period 10 years): every 6 months 
after the end of antiviral treatment for the first 2 years and every 24 months, subsequently. Cirrhotic 
patients were examined every 6 months. The liver-related events occurred during FU and 
considered for the analysis were collected from the outpatients’ registries and were: the 
development of cirrhosis and its complications (ascites, bleeding varices, hepatic encephalopathy 
and HCC). The diagnosis of HCC was done using imaging techniques. The cardiovascular events 
considered in the analysis included acute myocardial infarction and stroke.  
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Statistical analysis 
Data are reported as mean and standard deviation (SD) for continuous normally distributed 
variables, as median and interquartile range (25°-75° percentiles) for continuous non-normally 
distributed variables and as number and frequency (%) for categorical variables. Data normality was 
checked by D’Agostino-Pearson test. Comparisons between groups were performed using the two-
tailed Student’s t-test, for normal continuous variables, and the Kruskal-Wallis non-parametric test, 
for non-normal continuous variables. For categorical data, the Fisher exact test or the Chi-square 
test were used as appropriate. To assess the occurrence of liver/cardio-metabolic events over time, 
according to the presence of baseline metabolic cofactors, the Kaplan-Meier survival analysis was 
performed and differences between the curves were determined by the Logrank test. To evaluate the 
risk to develop clinical events in the FU, univariate and multivariable Cox regression analysis 
adjusted for age, sex and BMI were performed. All the analysis were performed with MedCalc 
software version 12.7. 
 
Results 
Clinical features of the study population at baseline 
A total of 188 CHC patients (114 male, 61%) were followed-up for 3 to 21 years (mean 11 years). 
Most of the patients (93%) were treated with the combination of pegylated IFN and RBV while the 
others received the IFN monotherapy. Baseline clinical, biochemical and histological characteristics 
of the study cohort, according to the presence or absence of HS, are reported in Table 1. HS was 
found at liver biopsy in 82 CHC patients with a prevalence of 43.6%. Patients with HS were older 
and showed a higher BMI compared to those without HS. Overall, 33 patients (17.6%) were 
infected by HCV genotype 3a and most of them (22 out of 33, 67%) had HS. Overall, the 
prevalence of obesity, IFG/T2D, dyslipidemia and arterial hypertension was 4.3%, 6.9%, 37.2% and 
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5.9%, respectively, and was not different in the two groups. Older age, HCV genotype 3a, and 
dyslipidemia were significantly associated to the presence of baseline HS at univariate logistic 
regression analysis but, after multivariable regression analysis, the only factor significantly 
associated to HS was HCV-genotype 3a (odds ratio [OR]=8.4; 95% confidence interval [CI] 2.7-
26.0, p<0.001) (Supplementary Table 1).  
 
Follow-up analysis 
After 20 years of follow-up, one CHC patient had a recurrence of HCV infection. Of the 6 deaths 
occurred, 2 LTRs died for liver-related events, 3 for cardiovascular events and 1 for colorectal 
cancer (Table 2). The cumulative incidence of mortality was similar in LTRs who had HS at biopsy 
compared to those who did not have HS (Table 2). 
 
Liver-related morbidity 
Liver-related events occurred in 5 LTRs with a cumulative incidence of 0.3%. One subject 
developed cirrhosis, 1 with pre-existent cirrhosis at baseline developed its complications (hepatic 
decompensation), 3 subjects developed HCC (2 on cirrhotic liver and 1 on non-cirrhotic liver with 
steatosis). Baseline HS did not impact on the development of liver-related events during follow-up 
(Table 2). Conversely, CHC-LTRs who had severe fibrosis at baseline showed a higher cumulative 
incidence of liver related outcomes compared to those with mild/moderate fibrosis (0.9% vs 0.1%, 
p<0.001) (Supplementary Table 2). After multivariable Cox regression analysis adjusted for age, 
sex, BMI and HCV genotypes, severe fibrosis was the only baseline predictor of liver-related 
outcomes with a hazard ratio (HR) of 11 (95% CI=1.5-87.9, p=0.025, data not shown).  
 
Cardiometabolic-related morbidity 
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Overall, cardiovascular events occurred in 14 LTRs and the cumulative incidence was significantly 
higher in those who had HS at liver biopsy compared to those without HS (1.2% vs 0.4%, p=0.011) 
(Table 2). At univariate Cox regression analysis, IFG/T2D, dyslipidemia and HS showed a higher 
probability to develop cardiovascular events (Figure 2 A-C). After multivariable Cox regression 
analysis, the only metabolic cofactor significantly associated to a higher risk of developing 
cardiovascular events was IFG/T2D (HR=5.2, 95% CI=1.3-20.7, p=0.019) (Table 3).  
Arterial hypertension occurred in 24 LTRs with a similar cumulative incidence in both patients with 
and without HS at liver biopsy (1.4% vs 1.3%, p=0.610) (Figure 2D). At univariate Cox regression 
analysis, no metabolic cofactors were significantly associated to the development of arterial 
hypertension over time, and multivariable analysis confirmed this result. 
Overall, the cumulative incidence of overweight/obesity, IFG/T2D and dyslipidemia was 1.2%, 
1.5% and 2.8%, respectively (Table 2). Specifically, the cumulative incidence of IFG/T2D and 
dyslipidemia was significantly higher in LTRs who had HS at liver biopsy compared to those who 
did not have HS (2.3% vs 0.8%, p=0.005 and 3.0% vs 2.5%, p=0.010, respectively), while the 
cumulative incidence of overweight/obesity was similar among the two groups.  
At univariate Cox regression analysis, older age, dyslipidemia and HS were significantly associated 
to the development of IFG/T2D. After multivariable analysis, the only baseline metabolic cofactor 
associated to the development of IFG/T2D was HS (HR=2.6, 95% CI=1.1-6.2, p=0.027) (Table 4). 
Concerning the other metabolic outcomes, older age increased the risk of developing dyslipidemia 
during follow-up (HR=1.0, 95% CI=1.0-1.1, p=0.005) (Supplementary Table 3) while no baseline 
cofactors increased the risk of overweight/obesity over time. 
 
Discussion 
In this study, on 188 CHC LTRs to IFN and RBV therapy, we assessed the impact of metabolic 
cofactors (HS, overweight/obesity, T2D, dyslipidemia and arterial hypertension) on the 
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development of clinical events (both hepatic and cardio-metabolic) during a long follow-up. 
Particularly, it is well known that HS may be considered as a marker of metabolic dysfunction 
predisposing to the development of clinical events even after a long time from HCV eradication. On 
the other side, CHC infection has been associated with a poor prognosis affecting both liver- and 
cardio-metabolic-related outcomes.17  
The median duration of FU was 11 years (range 3-21), one of the longer. Concerning virological 
and histological characteristics, our population slightly differs from another cohort of 150 Italian 
CHC-LTRs. In fact, in the former, the prevalence of HCV genotype 3a was higher compared to that 
reported by Morisco (17.6% vs 3.3%). Similarly the prevalence of cirrhosis was higher in our 
cohort compared to that reported in the other cohort (9.6% vs 1.3%).18  
At the time of baseline screening for antiviral therapy, HS was found at liver biopsy in 82 LTRs 
with a prevalence of 43.6%. This data was in agreement with several studies indicating that, in the 
setting of HCV infection, the prevalence of HS may range from 42% to 73%.19-20 It is well known 
that HS can be induced directly by HCV genotype 3a (viral steatosis) or indirectly, through the 
development of IR, by HCV-genotype 1 (metabolic steatosis).21-26 Particularly, HCV genotypes 1 
and 4 infection is associated to the development of IR regardless of the presence of steatosis.23, 27-28 
Recently, Lerat et al. demonstrated that in HCV transgenic mice, the development of IR and glucose 
intolerance are supported by HCV per se through the expression of viral proteins in the hepatocytes 
which negatively act on the glucose uptake by the liver through the down-regulation of Glut2 and 
IRS-2 expression via SOCS3-dependent mechanisms.28 Unfortunately, in our population we did not 
have data on homeostasis model of assessment (HOMA)-IR, but we showed that in HCV patients 
infected with HCV genotype non-3, baseline BMI was significantly higher compared to those 
infected with HCV genotype 3a indicating that in the first group, steatosis was mainly driven by 
metabolic rather than viral derangements. Conversely, 67% of HCV genotype 3a infected patients 
had HS at biopsy, probably driven by viral infection. 
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Overall, our population of LTRs had a good prognosis with a mortality rate of 0.3%, similar to that 
reported by Morisco et al. (0.7%) and by George et al. (0.6%) in two independent studies.18,29  
The cumulative incidence of IGF/T2D in our population is 1.5%, the same reported by Giordanino 
et al.30 In their study, the authors stated that HCV eradication did not significantly reduce the risk of 
IFG/T2D during 8 years FU and that the incidence of T2D was similar in LTRs compared to non-
responders at IFN or PegIFN plus RBV treatment.30 In another study, Metha et al. demonstrated that 
among 1084 non-diabetic subjects at baseline, HCV infection was associated with an elevated risk 
of T2D development over 9 years FU.31  
The incidence of cardiovascular events was 3-fold higher in CHC-LTRs who had HS at baseline 
compared to those without HS, and this data is comparable to that reported in the Italian 
population.32 The link between HCV infection and CAD is supported by the fact that HCV is able 
to interfere with both glucose and lipid metabolism, leading to the development of IR, HS and T2D, 
which are directly associated to atherosclerosis development.33 Furthermore, HCV increases 
cardiovascular risk by inducing a systemic inflammatory status and oxidative stress.33 Specifically, 
HCV infection promotes inflammation increasing pro-inflammatory cytokines levels such as 
interleukin (IL)-6, tumor necrosis factor alpha (TNF-a), C-reactive protein (CRP) and fibrinogen 
which in turn are associated with increased risk of CAD.34-35 
According to previous data, we confirm that hepatic fibrosis is the main risk factor for the 
development of hepatic complications.36-37 The incidence of HCC in our population was very low 
(0.2%) and similar between CHC-LTRs who had HS at baseline and those who did not have HS. 
The association between HS and fibrosis in the setting of HCV infection is controversial: while in 
the majority of the studies a robust association has been reported,38-40 some authors did not find any 
relationship.41  
Our study has some limitations. The first is the lack of a second liver biopsy making difficult the 
longitudinal comparison of the degree of hepatic fibrosis and steatosis. Nevertheless, from an 
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ethical point of view, in the clinical setting, it would be difficult to perform a second liver biopsy 
for histological revaluation. The second limitation is the retrospective design of the study making 
difficult to find clinical data from old medical records. Furthermore, during the last 30 years, all 
consultations has been recorded in both a paper archive and a digital databank. However, the 
potential heterogeneity arising from this, is limited by the fact that in our unit all authors followed 
international guidelines. Finally, we are aware that the lack of data on alcohol consumption in our 
cohort may represent another important limitation. However, all patients stopped drinking at the 
time of HCV diagnosis and during antiviral treatment.   
In conclusion, this study indicates that in a population of CHC-LTRs to IFN-based therapies, SVR 
is associated with a good prognosis. Notwithstanding this, the presence of HS at baseline may 
predispose to the development of cardiovascular events and T2D during follow-up emphasizing the 
importance of an accurate counseling in order to prevent extra-hepatic complications. 
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Tables 
Table 1. Baseline clinical, biochemical and histological characteristics of CHC infected patients in 
the whole cohort and according to the presence histological steatosis. 
Variables 
All 
(N=188) 
CHC 
(N=106) 
HS-CHC 
(N=82) 
P value 
Age (years) 46 ± 12 45 ± 12 48 ± 11 0.043 
M/F, n 114/74 (61/39) 58/48 (55/45) 56/26 (68/32) 0.082 
BMI (kg/m2) 24.3 ± 3.2 23.7 ± 3.0 25.1 ± 3.4 0.007 
HCV genotype, n (%) 
    1a/1b 
    2a/2c 
    3a 
    4 
 
111 (59.0) 
41 (21.8) 
33 (17.6) 
3 (1.6) 
 
67 (63.2) 
27 (25.5) 
11 (10.4) 
1 (0.9) 
 
44 (53.7) 
14 (17.1) 
22 (26.8) 
2 (2.4) 
0.019 
AST (U/L) 57 (55-67) 59 (52-72) 56 (55-67) 0.658 
ALT (U/L) 82 (78-93) 85 (76-97) 82 (77-104) 0.605 
gGT (U/L) 45 (37-52) 40 (34-45) 50 (34-67) 0.149 
Hb (g/dL) 14.6 ± 1.4 14.5 ± 1.3 14.7 ± 1.5 0.551 
Platelets (x109) 211 (201-220) 210 (206-232) 203 (187-220) 0.176 
Total cholesterol (mg/dL) 175 (168-182) 173 (160-179) 183 (168-193) 0.166 
Triglycerides (mg/dL) 101 (90-110) 98 (88-112) 102 (89-116) 0.253 
Glucose (mg/dL) 88 (84-91) 85 (83-88) 92 (88-95) 0.097 
Log10 HCV-RNA 5.86 ± 0.69 5.82 ± 0.62 5.91 ± 0.78 0.456 
Follow-up (years) 11 ± 4 12 ± 5 11 ±  4 0.412 
Histology     
Fibrosis mstage, n (%)    0.585 
     F1 23 (12.2) 16 (15.1) 7 (8.5)  
     F2 54 (28.7) 28 (26.4) 26 (31.7)  
     F3 63 (33.5) 36 (34.1) 27 (32.9)  
     F4 16 (8.5) 8 (7.5) 8 )9.8)  
     F5 14 (7.4) 8 (7.5) 6 (7.3)  
     F6 18 (9.6) 10 (9.4) 8 (9.8)  
Inflammation grading 4.8 ± 2.1 4.6 ± 1.9 5.1 ± 2.2 0.139 
Data are reported as mean ± standard deviation or as median (95% confidence interval for the median). ALT, 
alanine aminotransferases; AST, aspartate aminotransferases; BMI, body mass index; CHC, chronic hepatitis 
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C; F, female; gGT, glutamyl-aminotransferases; Hb, hemoglobin; HS, hepatic steatosis; M, male; SD, 
standard deviation.  
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Table 2. Liver-related and cardio-metabolic-related mortality/morbidity according to the presence  
of hepatic steatosis. 
Events (N) and  
cumulative incidence (%) 
All 
(N=188) 
No HS 
(N=106) 
HS 
(N=82) 
P 
Mortality 
All causes 
          Liver-related 
          Cardiovascular-related 
          Other causes 
 
6 (0.3) 
2 (0.1) 
3 (0.2) 
1 (0.05) 
 
2 (0.2) 
- 
1 (0.09) 
1 (0.09) 
 
4 (0.5) 
2 (0.2) 
2 (0.2) 
- 
 
0.144 
0.081 
0.342 
0.527 
Liver-related events 
Liver-related events 
          Cirrhosis and complications 
          HCC        
 
5 (0.3) 
2 (0.1) 
3 (0.2) 
 
3 (0.3) 
1 (0.1) 
2 (0.2) 
 
2 (0.2) 
1 (0.1) 
1 (0.1) 
 
0.978 
0.423 
0.848 
Cardiovascular events 
          CAD 
          Arterial hypertension 
 
14 (0.7) 
24 (1.3) 
 
4 (0.4) 
13 (1.2) 
 
10 (1.2) 
11 (1.3) 
 
0.011 
0.610 
Metabolic-related outcomes     
          Ow/Ob 22 (1.2) 10 (0.9) 12 (1.5) 0.073 
          IFG/T2D 28 (1.5) 9 (0.8) 19 (2.3) 0.005 
          Dyslipidemia 52 (2.8) 27 (2.5) 25 (3.0) 0.010 
 
The  cumulative incidence rate per 100 person-year was derived by the ratio of the number of events to the 
patient-years per 100. Group 1, long-term steatosis; group 2, incident steatosis; group 3, improved steatosis; 
group 4, no history of steatosis. 
The p value has been derived from the Logrank test and is referred to the comparison of survival curves. 
CAD, cardiovascular diseases; HCC, hepatocellular carcinoma; IFG, impaired fasting glucose; Ob, obese; 
Ow, overweight; T2D, type 2 diabetes mellitus.  
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Table 3. Univariate and multivariable Cox regression analysis of viral and metabolic cofactors 
associated to the development of cardiovascular events during follow-up. 
  
 Univariate analysis Multivariable analysis 
Variables OR (95% CI) P value OR (95% CI) P value 
Age  1.0 (0.9-1.1) 0.078 - - 
Sex (male) 2.0 (0.6-7.4) 0.281 - - 
BMI ≥ 24.9 kg/m2 1.7 (0.6-4.9) 0.838 - - 
HCV genotype 3a 0.4 (0.1-3.4) 0.430 - - 
HCV genotype 1a/b 0.9 (0.3-3.1) 0.999 - - 
IFG/T2D 7.7 (2.4-24.3) <0.001 5.2 (1.3-20.7) 0.019 
Dyslipidemia 3.5 (1.1-10.8) 0.028 - - 
Arterial hypertension 2.9 (0.6-13.0) 0.171 - - 
Hepatic steatosis 3.3 (1.0-10.7) 0.046 - - 
 
BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; IFG, impaired fasting glucose; OR, 
odd ratio; T2D, type 2 diabetes. 
	1	
	2	
	3	
	4	
	5	
	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	
	19	
	20	
	21	
	22	
	23	
	24	
	25	
	26	
	27	
	28	
	29	
	30	
	31	
	32	
	33	
	34	
	35	
	36	
	37	
	38	
	39	
	40	
	41	
	42	
	43	
	44	
	45	
	46	
	47	
	48	
	49	
	50	
	51	
	52	
	53	
	54	
	55	
Page 18 of 23
19 
 
Table 4. Univariate and multivariable Cox regression analysis of viral and metabolic cofactors 
associated to the development of glucose intolerance or type 2 diabetes during follow-up. 
 Univariate analysis Multivariable analysis 
Variables OR (95% CI) P value OR (95% CI) P value 
Age  1.1 (1.0-1.1) 0.001 1.1 (1.0-1.1) 0.008 
Sex (male) 0.8 (0.4-1.7) 0.570 - - 
BMI ≥ 24.9 kg/m2 1.7 (0.8-3.6) 0.171 - - 
HCV genotype 3a 0.7 (0.2-2.3) 0.541 - - 
HCV genotype 1a/b 0.6 (0.3-1.3) 0.224 - - 
Dyslipidemia 3.7 (1.6-8.4) 0.002 - - 
Arterial hypertension 0.8 (0.2-3.6) 0.779 - - 
Hepatic steatosis 3.1 (1.4-6.9) 0.005 2.6 (1.1-6.2) 0.027 
 
BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; IFG, impaired fasting glucose; OR, 
odd ratio; T2D, type 2 diabetes. 
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Figures legend 
Figure 1. Flow-chart of the study. 
HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; IFN, interferon; LTRs, long term responders; NR, non-
responders. 
 
Figure 2. Kaplan-Meier survival curves showing the probability to develop cardiovascular events 
according to the presence of impaired fasting glucose/type 2 diabetes (A), dyslipidemia (B) and 
hepatic steatosis (C) at baseline.  
Differences between the curves were determined by the Logrank test. 
FU, Follow-up; IFG, impaired fasting glucose; T2D, type 2 diabetes. 
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